Autonomic Testing for Neurology Practices: 9 Clear Answers

Autonomic testing for neurology practices is a defined in office workflow, not a new service line to figure out from scratch. A trained staff member runs a short battery of cardiovascular reflex maneuvers and sudomotor measurement on a patient who already has documented symptoms, and the neurologist interprets the tracings and decides what changes in management. The question most neurology practices actually need answered is narrower than whether to test at all. It is whether a compact in office system covers enough of the recognized autonomic domains to be clinically useful, what it plainly does not cover, and how the encounter gets documented so the record supports the work.

This guide answers those questions directly for independent neurology practices evaluating the CMAT Advantage system, which is built on FDA-cleared component devices from LD Technology. It is written for physicians and practice administrators, and it is deliberately explicit about the limits.

What this guide covers

• What autonomic testing for neurology practices actually measures
• Which patients it is appropriate for
• How the battery maps to the consensus domains
• What it does not replace
• What the test session looks like in clinic
• What changes in management the result drives
• Which CPT codes describe the work
• How to document medical necessity
• What to ask before you buy

What does autonomic testing for neurology practices actually measure?

The published consensus is the right starting point, because it defines the domains rather than the hardware. The 2021 consensus statement on electrodiagnostic assessment of the autonomic nervous system, endorsed by the American Autonomic Society, the American Academy of Neurology and the International Federation of Clinical Neurophysiology, states that grading and localization of autonomic deficits “incorporates scores from sympathetic cardiovascular adrenergic, parasympathetic cardiovagal, and sudomotor testing, as no single test alone is sufficient to diagnose the degree or distribution of autonomic failure” (Cheshire WP et al., Clinical Neurophysiology 2021;132(2):666 to 682).

That single sentence sets the bar. A device that returns one number is not doing autonomic testing in the sense the consensus describes. Any system a neurology practice brings in office should touch more than one domain, and the practice should be able to say which domain each output belongs to.

The same consensus statement lists valid indications, and they read like a neurology clinic schedule: generalized autonomic failure, regional or selective system syndromes of autonomic impairment, peripheral autonomic neuropathy and ganglionopathy, small fiber neuropathy, orthostatic hypotension, orthostatic intolerance, syncope, neurodegenerative disorders, autonomic hyperactivity, and anhidrosis.

Which patients is autonomic testing for neurology practices appropriate for?

Patients who already have documented symptoms or documented risk indications, and whose results will inform clinical management. That framing is not a legal nicety. It is the difference between defensible practice and the conduct that has drawn federal enforcement attention in this category, where the problem was providers testing symptomless patients, ignoring the results, and lacking training.

In practice the referrals that fit are the ones a neurologist already sees: unexplained syncope or near syncope, orthostatic intolerance, burning or lancinating distal pain with a normal large fiber examination, sudomotor complaints such as anhidrosis or focal sweating changes, and autonomic symptoms accompanying a known neurodegenerative diagnosis. Diabetes is the other common thread. In its position statement on diabetic neuropathy, the American Diabetes Association reports that prevalence rates of cardiovascular autonomic neuropathy “of at least 30% were observed in the DCCT/EDIC cohort after 20 years of diabetes duration” in type 1 diabetes, and that in type 2 diabetes it “may be present in up to 60% of patients with type 2 diabetes after 15 years” (Pop-Busui R et al., Diabetes Care 2017;40(1):136 to 154).

Those figures describe a population that already carries a diagnosis and often already carries symptoms. They are a reason to evaluate the patient in front of you carefully, and our related discussion of cardiovascular autonomic neuropathy goes further into how that presentation is worked up.

How does the battery map to the consensus domains?

This is the part worth being precise about, because it is where marketing language usually goes vague. The CMAT Advantage system, and the TM-Flow device inside it, performs a cardiac autonomic reflex battery documented in LD Technology’s instructions for use. The maneuvers run in a fixed sequence of Valsalva, then deep breathing, then standing.

An oscillometric cuff ankle brachial index is performed in the same session. So the battery touches all three consensus domains, which is the threshold the consensus statement sets. Our fuller explanation of autonomic nervous system testing methods walks through each maneuver in more depth, and the sudomotor testing and heart rate variability testing discussions cover those two components on their own terms.

It is worth noting how closely this matches the way the ADA position statement describes the standard approach, which it summarizes as cardiovascular autonomic reflex tests that “assess the changes in the R-R interval on electrocardiogram recordings in response to simple clinical maneuvers (deep breathing, Valsalva, and standing).” The maneuvers are the same three.

What does autonomic testing for neurology practices not replace?

Three limits deserve to be stated plainly before a practice buys anything.

• It is an active stand, not a passive head-up tilt. The standing maneuver measures the response to the patient standing up under their own power. A practice that needs formal tilt table protocols will still refer those patients to a laboratory that has a tilt table.
• Sudomotor measurement here is a sympathetic skin response, not QSART. Quantitative sudomotor axon reflex testing and thermoregulatory sweat testing are different methods with different equipment and different normative data. If a specific referral question requires QSART, this does not answer it.
• It does not interpret itself. The system produces the tracings and the report. The neurologist reads them, correlates them with the examination, and decides what to do. LD Technology’s software instructs the interpreting physician to choose the relevant codes, and it names none.

A practice that is honest about these three limits will position the system correctly with referring physicians, which matters more over time than any feature list. For patients whose presentation points at distal small fiber involvement, our discussion of small fiber neuropathy testing covers what the workup usually includes.

What does the test session look like in a neurology clinic?

Short, and that is the operational point. The session shape is the thing most practices misjudge when they first cost out autonomic testing for neurology practices. The test itself runs about 7 to 10 minutes once staff are practiced, which means it fits inside an existing visit slot rather than requiring a dedicated half day. The patient sits for a rest period first, and that rest period is not optional. LD’s current instructions for use call for the patient to be at rest for at least 15 minutes before measurement, and skipping it is the most common way a practice generates tracings it cannot use. Our guide to TM-Flow test preparation covers the setup steps in order.

Staffing is usually the deciding factor rather than physician time. A medical assistant or nurse can be trained to run the battery, and training is included with a CMAT Advantage purchase. The device and its reporting software run on the system in your office. Results are generated there and printed or saved to the chart the same day.

One workflow detail that neurology practices raise often: patients presenting with orthostatic complaints frequently need the postural component read alongside a careful bedside blood pressure protocol, and our page on orthostatic hypotension testing sets out how that measurement is standardly performed.

What changes in management does a result actually drive?

This is the question that decides whether autonomic testing for neurology practices belongs in your clinic, and it is also the question a reviewer asks when a chart is examined. A study that never changes anything is a study that should not have been ordered. Four patterns come up repeatedly.

• Reduced cardiovagal indices in a patient with diabetes and unexplained resting tachycardia. The finding is relevant to how the clinician frames cardiovascular risk in that patient and to the conversation about symptom monitoring. It is information that informs management rather than a treatment in itself.
• A blood pressure drop on standing in a patient reporting presyncope. The usual next steps are a careful medication review, since many commonly prescribed drugs contribute, along with counselling on volume, position changes and pacing. Our page on orthostatic hypotension testing covers the measurement protocol in more detail.
• Abnormal sudomotor findings with a normal large fiber examination. That combination supports a distal small fiber process and points the remainder of the workup in a specific direction rather than a general one.
• A normal study in a symptomatic patient. This is genuinely useful and is often undervalued. A normal battery redirects the differential and can stop a patient being cycled through repeat testing.

In every one of those four cases the important step is the same: write down what the result changed. The interpretation and the management decision belong in the note together. That habit is what makes autonomic testing for neurology practices defensible over years rather than merely accurate on the day.

Which CPT codes describe this work?

Three codes are relevant to the components of autonomic testing for neurology practices described above, and each describes a distinct service:

1. 95921, cardiovagal innervation testing. The descriptor calls for two or more of the deep breathing heart rate response, the Valsalva ratio, and the 30:15 ratio. The battery above documents all three.
2. 95923, sudomotor function testing.
3. 93923, the complete bilateral noninvasive physiologic study, which is the code that describes the ankle brachial index work performed in the session.

Two cautions belong with that list. First, code selection is the interpreting physician’s responsibility and always depends on what was actually performed and documented. Second, coverage is governed by your Medicare Administrative Contractor’s local coverage determination, and those vary. Confirm the current policy with your MAC before you build a workflow around any assumption about payment. Our walkthrough of coding the CMAT encounter and the reference page on the autonomic function testing CPT code family go into the detail.

How should medical necessity be documented?

The documentation standard for autonomic testing for neurology practices is simple to state and easy to get wrong. Document the symptoms or risk indications before the test is ordered, not afterward. Then record what the results changed. A chart that shows a symptomatic presentation, an order tied to a specific clinical question, an interpretation signed by the physician, and a management decision that references the findings is a chart that reflects the work that was done.

The failure pattern is the opposite of that, and it is well documented in enforcement actions across this device category: batch testing, no symptom documentation, results filed without interpretation, and untrained operators. None of those are device problems. They are workflow problems, and they are avoidable by design.

Is autonomic testing for neurology practices worth bringing in house?

It depends on referral volume and on whether the questions your patients present with sit inside the domains the battery covers. A practice sending a steady stream of patients out for autonomic evaluation, waiting weeks for results, and then re-scheduling the follow up has a real workflow argument for keeping the study in office. A practice whose autonomic referrals are mostly tilt table questions or QSART questions does not, and should say so.

The honest summary is that autonomic testing for neurology practices is a good fit where the clinical questions are cardiovagal, adrenergic and sudomotor, where patients are symptomatic, and where someone in the practice will own the workflow. It is a poor fit where any of those three are missing.

What should you ask before you buy?

Five questions separate a useful conversation from a demonstration. Ask any vendor offering autonomic testing for neurology practices to answer them plainly, in writing where possible.

1. Which consensus domain does each output belong to? If a vendor cannot map their outputs to cardiovagal, adrenergic and sudomotor, that is your answer.
2. What is the regulatory status, and who holds the clearance? Ask for the pathway and the holder by name, not a general assurance.
3. What does the study not cover? A vendor who says it covers everything is describing a product that does not exist.
4. What is the rest and preparation protocol, and where is it documented? Ask to see the manufacturer’s instructions for use rather than a sales sheet.
5. What training is included, and who delivers it? Operator competence is the variable most closely tied to whether the tracings are usable.

We will answer all five for the CMAT Advantage system without a discovery call first. If the answers rule out autonomic testing for neurology practices in your setting, that is a useful outcome too.

Frequently asked questions

Does autonomic testing for neurology practices require a dedicated room?

No. It needs a quiet space where the patient can rest undisturbed for at least 15 minutes and then be positioned for the maneuvers. Most practices use an existing exam room rather than dedicating one.

Who is allowed to perform the test?

Trained clinical staff can run the battery under the supervision rules that apply in your setting, and the interpreting physician signs the interpretation. Supervision and billing rules differ by service and by contractor, so confirm the specifics with your MAC.

Is the CMAT Advantage system FDA approved?

No, and the distinction matters. It is built on FDA-cleared component devices, cleared through the 510(k) pathway, and that clearance is held by LD Technology. Clearance and approval are different regulatory routes, and describing a 510(k) device as approved is inaccurate.

Does the system replace a formal autonomic laboratory?

No. It covers the three consensus domains with an active stand protocol and a sympathetic skin response. Tilt table studies and QSART remain laboratory studies, and patients whose referral question requires them should be referred.

How long does a patient need to rest before testing?

At least 15 minutes, per LD Technology’s current instructions for use. Shortening the rest period is the most common cause of tracings that cannot be interpreted.

Talk it through with us

If you are weighing autonomic testing for neurology practices and want a straight answer about whether it fits your referral mix, we would rather tell you it does not than sell you something you will not use. HealthWright Technologies is at 60 Bear Creek Marina Rd, Mansfield, GA 30055. Email contact@healthwrighttechnologies.com or use our contact page and we will follow up. A demonstration runs about 25 minutes.

Consult your healthcare provider before starting any new treatment.

CPT is a registered trademark of the American Medical Association. All CPT code descriptions and references are the property of the AMA. Code selection, documentation and billing are the responsibility of the ordering and interpreting provider, and coverage is determined by the applicable Medicare Administrative Contractor policy. Nothing here guarantees coverage or payment.